Analysts Insights on Ziopharm Oncology In (ZIOP)

Jeannie Matthews
January 13, 2018

Analysts await Acacia Research Corporation (NASDAQ:ACTG) to report earnings on March, 8. ZIOPHARM Oncology, Inc. (ZIOP) has had a 20-day average volume of 1,865,085 shares, with an average of 20% of short term indicators pointed at Sell. The company is scheduled to report its next earnings report on Thursday, February 15th.

Wall Street analysts are predicting that Ziopharm Oncology In (NASDAQ:ZIOP) will report earnings per share of $-0.13 in their quarterly report. The company's revenue was up.0% on a year-over-year basis. equities research analysts expect that ZIOPHARM Oncology will post -0.54 earnings per share for the current fiscal year. Zacks Investment Research's earnings per share calculations are an average based on a survey of research firms that that provide coverage for ZIOPHARM Oncology. For the most recent quarter, quick ratio was 6.3, current ratio was 6.3, LT Debt/Equity ratio was 0 and Total Debt/Equity ratio stands at 0, while Payout ratio is 0. However the low revenue estimates for the company are $1.46 Million versus high revenue estimates of $1.7 Million. The Company's year to date (YTD) performance is now negative at -0.24%.

Total debt to equity ratio of the company for most recent quarter is 0.29 while Long term debt to equity ratio for same time period is 0.14. ValuEngine downgraded shares of ZIOPHARM Oncology from a hold rating to a sell rating in a research note on Friday, September 15th. Raymond James Financial restated a "hold" rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. Zacks Investment Research raised shares of ZIOPHARM Oncology from a hold rating to a buy rating and set a $5.25 target price for the company in a research report on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company's stock. According to the latest data, the consensus recommendation for ZIOPHARM Oncology, Inc. BB&T Securities LLC purchased a new stake in ZIOPHARM Oncology in the 2nd quarter worth approximately $112,000. The company's beta value stood at 1.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.40% of the company's stock. Of those transactions, there were 683,742 shares of ZIOP bought and 438,123 shares sold. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has risen 1.75% since January 11, 2017 and is uptrending. Amalgamated Bank increased its position in ZIOPHARM Oncology by 12.9% during the 2nd quarter. Of the 20 analysts surveyed by Reuters that track AIG 9 of them rate its stock a hold. Northern Trust Corp lifted its stake in ZIOPHARM Oncology by 10.1% during the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company's stock valued at $105,000 after buying an additional 1,924 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its stake in ZIOPHARM Oncology by 6.8% during the second quarter. Ziopharm Oncology In (NASDAQ:ZIOP)'s price sits -2.62% off from its 50-day moving average of $4.29 and -25.45% away from the stock's 200-day moving average which is $5.34.

ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.13 on Thursday.

Sevilla keen on loan deal for Chelsea's Michy Batshuayi
Antonio Conte has insisted he is "very happy" with Michy Batshuayi amid speculation the striker could leave Chelsea in January. Batshuayi snubbed West Ham for Chelsea in 2016 after the Hammers had a £30million bid accepted by Marseille.

$1.13 EPS Expected for Cardinal Health, Inc. (CAH) This Quarter
The rating was maintained by William Blair on Wednesday, August 26 with "Buy". (NYSE:PPG) on Monday, October 2 with "Buy" rating. The company has a market cap of $21,410.00, a PE ratio of 19.84, a price-to-earnings-growth ratio of 1.84 and a beta of 0.85.

Villarreal Stun Real Madrid At The Bernabeu
The La Liga match between Real Madrid and Villarreal will be broadcast live on beIN Sports. As far as is concerned, things are not as bad as they look for Real Madrid .

Changing lanes, the 100-day moving average verse price signal is Sell for Prologis Inc (PLD). The indicator is non-directional meaning that it gauges trend strength whether the stock price is trending higher or lower.

However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.

ILLEGAL ACTIVITY NOTICE: This story was reported by StockNewsTimes and is the property of of StockNewsTimes.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The Company's synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

Other reports by

Discuss This Article